Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)

Zhanna D. Kobalava

6 Miklukho Maklaya Str, 
Moscow, MOW, RU 
Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)
6 Miklukho Maklaya Str, 
Moscow, MOW, RU 
OverviewLocationsClinical Research

Overview

Zhanna Kobalava practices in Moscow, Russian Federation. Ms. Kobalava is rated as an Experienced expert by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). Her top areas of expertise are Hypertension, Heart Failure, Infective Endocarditis, and Endocarditis.

Her clinical research consists of co-authoring 35 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

6 Miklukho Maklaya Str, Moscow, MOW 117198, Russian Federation

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency /and Sub-Study
A Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency /and Sub-Study
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: Ferric Carboxymaltose
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection
Enrollment Status: Completed
Publish Date: July 28, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 1 Less Clinical Trial

35 Total Publications

Corrigendum to "HIV-Related Atherosclerosis: State-of-the-Art-Review" [Current Problems in Cardiology, Volume 48, Issue 9, September 2023, 101783].
Corrigendum to "HIV-Related Atherosclerosis: State-of-the-Art-Review" [Current Problems in Cardiology, Volume 48, Issue 9, September 2023, 101783].
Journal: Current problems in cardiology
Published: November 27, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Kobalava's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile